In recent trading session, Novo Nordisk ADR (NYSE:NVO) saw 2.83 million shares changing hands at last check today with its beta currently measuring 0.42. Company’s recent per share price level of $120.66 trading at -$3.64 or -2.93% at last check today assigns it a market valuation of $402.81B. That most recent trading price of NVO’s stock is at a discount of -22.78% from its 52-week high price of $148.15 and is indicating a premium of 27.93% from its 52-week low price of $86.96. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 4.22 million shares which gives us an average trading volume of 3.90 million if we extend that period to 3-months.
For Novo Nordisk ADR (NVO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.94. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0.91 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Novo Nordisk ADR (NYSE:NVO) trade information
Upright in the red during last session for losing -2.93%, in the last five days NVO remained trading in the red while hitting it’s week-highest on Wednesday, 09/25/24 when the stock touched $120.66 price level, adding 5.45% to its value on the day. Novo Nordisk ADR’s shares saw a change of 16.64% in year-to-date performance and have moved -5.37% in past 5-day. Novo Nordisk ADR (NYSE:NVO) showed a performance of -10.28% in past 30-days. Number of shares sold short was 5.8 million shares which calculate 2.4 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 160 to the stock, which implies a rise of 24.59% to its recent value today. Analysts have been projecting 156 as a low price target for the stock while placing it at a high target of 160. It follows that stock’s current price would drop -29.29% in reaching the projected high whereas dropping to the targeted low would mean a loss of -29.29% for stock’s current value.
Novo Nordisk ADR (NVO) estimates and forecasts
Statistics highlight that Novo Nordisk ADR is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -6.03% of value to its shares in past 6 months, showing an annual growth rate of 15.19% while that of industry is 6.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 30.30% from the last financial year’s standing.
5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 10.91B for the same. And 4 analysts are in estimates of company making revenue of 11.98B in the next quarter. Company posted 8.55B and 9.4B of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 16.48% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 24.96% while estimates for its earnings growth in next 5 years are of 2.80%.
NVO Dividends
Novo Nordisk ADR is more likely to be releasing its next quarterly report on 2024-Nov-06 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt. With an annual yield of 1.20%, the share has a forward dividend of 1.45 which implies that company’s dividend yield remained growing in trailing twelve months while having a 5 year average dividend yield of 1.5%.
Novo Nordisk ADR (NYSE:NVO)’s Major holders
JENNISON ASSOCIATES LLC is the top institutional holder at NVO for having 21.22 million shares of worth $3.03 billion. And as of 2024-06-30, it was holding 0.4758 of the company’s outstanding shares.
The second largest institutional holder is FMR LLC, which was holding about 19.49 million shares on 2024-06-30. The number of shares represents firm’s hold over 0.4371 of outstanding shares, having a total worth of $2.78 billion.
